Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, Keyur Desai, Michele Maio, Korey Demers, Antonella Mazzei, Sarah Keidel, Karen Miller-Moslin, Jia Xin Yu, F. Stephen Hodi, Dirk Schadendorf, Georgina V. Long, Charlie Garnett-Benson
{"title":"在RELATIVITY-047中,使用生物标志物分析晚期黑色素瘤患者的相关抗体特异性生物学","authors":"Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, Keyur Desai, Michele Maio, Korey Demers, Antonella Mazzei, Sarah Keidel, Karen Miller-Moslin, Jia Xin Yu, F. Stephen Hodi, Dirk Schadendorf, Georgina V. Long, Charlie Garnett-Benson","doi":"10.1158/1078-0432.ccr-24-2499","DOIUrl":null,"url":null,"abstract":"Purpose: Administration of the lymphocyte-activation gene-3 (LAG-3) inhibitor relatlimab (RELA) and programmed death-1 (PD-1) inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced melanoma treated in RELATIVITY-047. This report describes correlative analyses of biospecimens collected within that trial to better understand mechanisms of action and identify patients who could benefit from treatment with NIVO + RELA. Patients and Methods: Pre- and on-treatment peripheral blood samples from 563 patients were analyzed by flow cytometry for changes in 77 pre-specified immune cell populations, and by immunoassay for peripheral interferon gamma (IFNγ). Pre-treatment tumor biopsies were evaluated using immunohistochemistry and RNA sequencing. Results: On-treatment expansion of 25 peripheral immune cell populations was significantly greater with NIVO + RELA versus NIVO alone. Responders to NIVO + RELA had greater on-treatment increases in LAG-3+CD4+ T cells than non‑responders. Significantly greater increases in peripheral IFNγ occurred after treatment with NIVO + RELA versus NIVO alone. A longer PFS was observed in patients treated with NIVO + RELA whose tumors had low CD8 expression compared with the NIVO arm. When evaluating co-expression of CD8 and LAG-3, patients whose tumors had high CD8+LAG-3+ also showed a PFS benefit with NIVO + RELA versus NIVO. RNA sequencing revealed several distinct gene signatures associated with response to NIVO + RELA. Conclusions: These results highlight the unique biological effects of RELA in combination with NIVO and provide further understanding of the patient characteristics associated with increased benefit from NIVO + RELA.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"69 1","pages":""},"PeriodicalIF":10.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047\",\"authors\":\"Evan J. Lipson, Sonia Dolfi, Hao Tang, Hussein A. Tawbi, Francisco Medina-Soto, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Emilio Murillo, Paolo A. Ascierto, Keyur Desai, Michele Maio, Korey Demers, Antonella Mazzei, Sarah Keidel, Karen Miller-Moslin, Jia Xin Yu, F. Stephen Hodi, Dirk Schadendorf, Georgina V. Long, Charlie Garnett-Benson\",\"doi\":\"10.1158/1078-0432.ccr-24-2499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Administration of the lymphocyte-activation gene-3 (LAG-3) inhibitor relatlimab (RELA) and programmed death-1 (PD-1) inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced melanoma treated in RELATIVITY-047. This report describes correlative analyses of biospecimens collected within that trial to better understand mechanisms of action and identify patients who could benefit from treatment with NIVO + RELA. Patients and Methods: Pre- and on-treatment peripheral blood samples from 563 patients were analyzed by flow cytometry for changes in 77 pre-specified immune cell populations, and by immunoassay for peripheral interferon gamma (IFNγ). Pre-treatment tumor biopsies were evaluated using immunohistochemistry and RNA sequencing. Results: On-treatment expansion of 25 peripheral immune cell populations was significantly greater with NIVO + RELA versus NIVO alone. Responders to NIVO + RELA had greater on-treatment increases in LAG-3+CD4+ T cells than non‑responders. Significantly greater increases in peripheral IFNγ occurred after treatment with NIVO + RELA versus NIVO alone. A longer PFS was observed in patients treated with NIVO + RELA whose tumors had low CD8 expression compared with the NIVO arm. When evaluating co-expression of CD8 and LAG-3, patients whose tumors had high CD8+LAG-3+ also showed a PFS benefit with NIVO + RELA versus NIVO. RNA sequencing revealed several distinct gene signatures associated with response to NIVO + RELA. Conclusions: These results highlight the unique biological effects of RELA in combination with NIVO and provide further understanding of the patient characteristics associated with increased benefit from NIVO + RELA.\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\"69 1\",\"pages\":\"\"},\"PeriodicalIF\":10.2000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.ccr-24-2499\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.ccr-24-2499","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047
Purpose: Administration of the lymphocyte-activation gene-3 (LAG-3) inhibitor relatlimab (RELA) and programmed death-1 (PD-1) inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced melanoma treated in RELATIVITY-047. This report describes correlative analyses of biospecimens collected within that trial to better understand mechanisms of action and identify patients who could benefit from treatment with NIVO + RELA. Patients and Methods: Pre- and on-treatment peripheral blood samples from 563 patients were analyzed by flow cytometry for changes in 77 pre-specified immune cell populations, and by immunoassay for peripheral interferon gamma (IFNγ). Pre-treatment tumor biopsies were evaluated using immunohistochemistry and RNA sequencing. Results: On-treatment expansion of 25 peripheral immune cell populations was significantly greater with NIVO + RELA versus NIVO alone. Responders to NIVO + RELA had greater on-treatment increases in LAG-3+CD4+ T cells than non‑responders. Significantly greater increases in peripheral IFNγ occurred after treatment with NIVO + RELA versus NIVO alone. A longer PFS was observed in patients treated with NIVO + RELA whose tumors had low CD8 expression compared with the NIVO arm. When evaluating co-expression of CD8 and LAG-3, patients whose tumors had high CD8+LAG-3+ also showed a PFS benefit with NIVO + RELA versus NIVO. RNA sequencing revealed several distinct gene signatures associated with response to NIVO + RELA. Conclusions: These results highlight the unique biological effects of RELA in combination with NIVO and provide further understanding of the patient characteristics associated with increased benefit from NIVO + RELA.
期刊介绍:
Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.